Biopark signs up for France's LEEM
The French drug industry association (LEEM) has welcomed Genopole, its 10th associate member, with a statement of intention to assemble "businesses which exercise an activity in the life sciences domain and which also contribute to the research or the bringing to market of health care products."
The Genopole is France's first biopark and has already collaborated with the LEEM in a number of projects. In April this year, the two organizations co-sponsored a symposium on the European Commission and the European Federation of Pharmaceutical Industries and Associations' Innovative Medicines Initiative (Marketletters passim).
Pierre Tambourin, the Genopole's director, announced a series of areas where the two groups will be working together in 2008, including a study of the attractiveness of France for biotechnology drug R&D and another on the sharing of expertise among specialist firms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze